{"title":"印度年轻发病肺癌:临床、人口统计学和基因组分析。","authors":"Prabhat Singh Malik, Neha Pathak, Aparna Sharma, Meghna Birla, Abhay Rastogi, Abha Sharma, Sachin Khurana, Deepam Pushpam, Ishaan Gupta, Amber Rathore, Deepali Jain, Sunil Kumar, Sushmita Pathy, Rajiv Kaushal, Vanita Noronha, Kumar Prabhash, Aarati Karaba, Vijayshree Gauribidanur Raghavendrachar, Nagesh Muniyappa","doi":"10.1016/j.cllc.2025.02.014","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Lung cancer (LC) is traditionally perceived as a disease primarily affecting the elderly. However, individuals under the age of 40 represent a rare subset, accounting for up to 6% of all LC cases. There is limited information about demographic, clinical, pathological, and molecular features and treatment outcomes of young-onset LC.</p><p><strong>Methods: </strong>In this study, we have analyzed the clinical, pathological, molecular, treatment, and survival outcome data of non-small-cell lung cancer patients δ 40 years of age treated at a tertiary care center in India. Additionally, we compared the in-house genomic data of young-onset LC and late-onset LC tested on a common targeted next-generation sequencing (NGS) panel.</p><p><strong>Results: </strong>A total of 133 patients were included, with a median age of 36 years (21-40 years). Females constituted 40.6% of total, and 79% were never smokers. Adenocarcinoma was the most common histology (85.7%), and oncogene fusions were common (ALK fusion in 34% and ROS1 in 7%). After a median follow-up of 39.2 months (95% CI 20.3-49.86), median overall survival was 26 months (95% CI 15.56-32.43) and median progression-free survival (of patients with stage 4 disease) was 6.53 months (95% CI 5.03-8.4). In-house NGS data reveals a striking enrichment of fusions (ALK and RET) in young-onset LC.</p><p><strong>Conclusion: </strong>Young-onset LC is a unique entity with a higher prevalence of targetable genomic alterations, especially oncogene fusions. All efforts should be made to identify the targetable alterations in this enriched population and implement targeted therapy.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Young Onset Lung Cancer in India: Insights Into Clinical, Demographic, and Genomic Profiles.\",\"authors\":\"Prabhat Singh Malik, Neha Pathak, Aparna Sharma, Meghna Birla, Abhay Rastogi, Abha Sharma, Sachin Khurana, Deepam Pushpam, Ishaan Gupta, Amber Rathore, Deepali Jain, Sunil Kumar, Sushmita Pathy, Rajiv Kaushal, Vanita Noronha, Kumar Prabhash, Aarati Karaba, Vijayshree Gauribidanur Raghavendrachar, Nagesh Muniyappa\",\"doi\":\"10.1016/j.cllc.2025.02.014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Lung cancer (LC) is traditionally perceived as a disease primarily affecting the elderly. However, individuals under the age of 40 represent a rare subset, accounting for up to 6% of all LC cases. There is limited information about demographic, clinical, pathological, and molecular features and treatment outcomes of young-onset LC.</p><p><strong>Methods: </strong>In this study, we have analyzed the clinical, pathological, molecular, treatment, and survival outcome data of non-small-cell lung cancer patients δ 40 years of age treated at a tertiary care center in India. Additionally, we compared the in-house genomic data of young-onset LC and late-onset LC tested on a common targeted next-generation sequencing (NGS) panel.</p><p><strong>Results: </strong>A total of 133 patients were included, with a median age of 36 years (21-40 years). Females constituted 40.6% of total, and 79% were never smokers. Adenocarcinoma was the most common histology (85.7%), and oncogene fusions were common (ALK fusion in 34% and ROS1 in 7%). After a median follow-up of 39.2 months (95% CI 20.3-49.86), median overall survival was 26 months (95% CI 15.56-32.43) and median progression-free survival (of patients with stage 4 disease) was 6.53 months (95% CI 5.03-8.4). In-house NGS data reveals a striking enrichment of fusions (ALK and RET) in young-onset LC.</p><p><strong>Conclusion: </strong>Young-onset LC is a unique entity with a higher prevalence of targetable genomic alterations, especially oncogene fusions. All efforts should be made to identify the targetable alterations in this enriched population and implement targeted therapy.</p>\",\"PeriodicalId\":10490,\"journal\":{\"name\":\"Clinical lung cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-02-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical lung cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cllc.2025.02.014\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cllc.2025.02.014","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:肺癌(LC)传统上被认为是一种主要影响老年人的疾病。然而,40岁以下的个体代表一个罕见的子集,占所有LC病例的6%。关于年轻发病的LC的人口学、临床、病理和分子特征以及治疗结果的信息有限。方法:在这项研究中,我们分析了在印度一家三级医疗中心治疗的40岁以上非小细胞肺癌患者的临床、病理、分子、治疗和生存结局数据。此外,我们比较了在共同靶向下一代测序(NGS)面板上测试的年轻发病LC和晚发病LC的内部基因组数据。结果:共纳入133例患者,中位年龄36岁(21-40岁)。女性占总数的40.6%,其中79%从不吸烟。腺癌是最常见的组织学(85.7%),癌基因融合是常见的(ALK融合34%,ROS1融合7%)。中位随访时间为39.2个月(95% CI 20.3-49.86),中位总生存期为26个月(95% CI 15.56-32.43),中位无进展生存期(4期患者)为6.53个月(95% CI 5.03-8.4)。内部NGS数据显示,在年轻发病的LC中,融合(ALK和RET)显著富集。结论:年轻起病的LC是一种独特的实体,具有更高的可靶向基因组改变发生率,特别是癌基因融合。应尽一切努力在这一富集人群中确定可靶向的改变并实施靶向治疗。
Young Onset Lung Cancer in India: Insights Into Clinical, Demographic, and Genomic Profiles.
Background: Lung cancer (LC) is traditionally perceived as a disease primarily affecting the elderly. However, individuals under the age of 40 represent a rare subset, accounting for up to 6% of all LC cases. There is limited information about demographic, clinical, pathological, and molecular features and treatment outcomes of young-onset LC.
Methods: In this study, we have analyzed the clinical, pathological, molecular, treatment, and survival outcome data of non-small-cell lung cancer patients δ 40 years of age treated at a tertiary care center in India. Additionally, we compared the in-house genomic data of young-onset LC and late-onset LC tested on a common targeted next-generation sequencing (NGS) panel.
Results: A total of 133 patients were included, with a median age of 36 years (21-40 years). Females constituted 40.6% of total, and 79% were never smokers. Adenocarcinoma was the most common histology (85.7%), and oncogene fusions were common (ALK fusion in 34% and ROS1 in 7%). After a median follow-up of 39.2 months (95% CI 20.3-49.86), median overall survival was 26 months (95% CI 15.56-32.43) and median progression-free survival (of patients with stage 4 disease) was 6.53 months (95% CI 5.03-8.4). In-house NGS data reveals a striking enrichment of fusions (ALK and RET) in young-onset LC.
Conclusion: Young-onset LC is a unique entity with a higher prevalence of targetable genomic alterations, especially oncogene fusions. All efforts should be made to identify the targetable alterations in this enriched population and implement targeted therapy.
期刊介绍:
Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.